Weei/nesn Jimmy Fund Radio-telethon

In 2012, Barry noticed some swelling on his neck, so he made an appointment to see his primary care physician. An x-ray and CT scan lead to follow-up appointments with various specialists until he was diagnosed with Stage 3B non-small cell lung cancer. Barry was initially going to get treatment at another institution but stopped at Dana-Farber to get a second opinion from Dr. Lathan. He recalls Dr. Lathan telling him they’d use all the tools in the toolbox and fight as hard as he could. From there, Barry knew he was in the right place. The treatment caused his tumors to shrink significantly and gave him his life back. Today, he’s no longer in active treatment, but returns to Dana-Farber for a follow-up every 6 months. Barry also volunteers as a patient advocate at Dana-Farber and Brigham & Women’s Hospital. He echoes that everything done at Dana-Farber is done with love and integrity, and he’s honored to be a part of that too. Lung cancer is the second most common cancer (not counting skin cancer) in both

Mary Lee went to her PCP following leg and back pain she was experiencing in June2017. It was initially chalked up as possibly sciatica, but when the pain persisted, she went to an orthopedic surgeon, and a subsequent MRI revealed cancer. Her doctors said her cancer was stage 4 and recommended she come to Dana-Farber. Types and length of treatments: She started treatment in 2017, went for chemo everyweek until 2019. Her cancer went into remission and then is often the case with her type of disease it returned and had spread. She went on a couple of different clinical trials which have helped keep her cancer at bay. She is feeling great today. She is very happy she ended up at Dana-Farber and is simply “glad to still be here.” Ovarian cancer isn’t diagnosed until it has progressed to an advanced stage. This is because ovarian cancer symptoms either aren’t apparent in the early stages of the disease or they mimic common stomach and digestive issues that are often mistaken for minor ailments. Ursula A. Matulonis

Head coach of the BC Eagles Jeff Hafley discusses his connection to the Jimmy Fund regarding his family and the upcoming football season and what he likes the most about his group.

Red Sox pitcher Nick Pivetta joins to talk about how he ingrained himself to the Jimmy Fund when he came to Boston and gives his insights from the clubhouse as the team's chase for the playoffs gets a little tougher.

Following some discomfort, Natalia underwent a colonoscopy in February of 2022. She was officially diagnosed with colon cancer after the procedure. Her doctors also believed that the cancer may be hereditary in nature because Natalia’s mother had uterine cancer. Additional genetic testing also confirmed that she had Lynch Syndrome, a genetic condition that greatly increases a person’s chance of developing cancer, including colon cancer. After the diagnosis, she underwent tumor removal surgery at Dana-Farber, and then started on a chemotherapy and immunotherapy combination treatment. Immunotherapy is a newer type of cancer treatment that allows the body’s own immune system to recognize and destroy cancer cells. She had been traveling back and forth from Seattle to Boston for treatment, which she completed in June. Today,she is cancer-free. In her free time, Natalia enjoys going to museums and shops, like Newbury Street when she’s in Boston. This visit is her daughter’s first time coming to see Boston! Natalie

Red Sox manager Alex Cora joins to talk about what the Jimmy Fund means to him and how he is approaching the last month of the regular season as the playoff chase gets more and more tighter.

Joe Andruzzi reflects on his fight that forced him to retire from football and the continued work from his foundation "The Joe Andruzzi Foundation."

Magnolia joined Dana-Farber in 2007 and currently serves as the Vice President of Community Health. In this role, she is charged with helping the Institute carry out its community benefits mission through the delivery of evidence-based cancer prevention, screening, and early detection programs. Magnolia and her team work with city and state health departments, community partners, and Boston-based coalitions to assess and monitor the needs of local residents with respect to cancercontrol. They are on the front lines of supporting and collaborating on programs designed to eliminate disparities in breast, colon, and skin cancer; educate diverse populations about tobacco cessation, human papillomavirus (HPV) prevention and screening.

Elevated PSA (prostate specific antigen levels) lead to Henry undergoing a biopsy, which revealed stage IV prostate cancer. He was officially diagnosed on August 13, 2021. He went to the doctor after getting a hemorrhoid while offshore fishing. His primary care doctor was the one who suggested also checking his PSA levels as a routine matter of care. A month after diagnosis, Henry underwent surgery toremove his prostate, seminal vesicles, and 27 pelvic lymph nodes, 8 of which were metastatic. After the surgery, surgical margins were deemed positive, meaning cancer cells were still present on the edges of the tissue. In response, Henry started systemic drug therapy in November and later, 40 sessions of radiation from January through March 2022. He is still in treatment and continuing the systemic drug therapy. Henry points out that he feels like more than a number at Dana-Farber because of the continued care and compassion that he receives: ranging from the nurses to radiation therapy technicians. Traveling in

In early March of 2018, at age 58, Roger Miller went to a local doctor’s office in Maine for outpatient surgery. He’d been putting off getting what he’d thought was a cyst removed from the back of his head. Miller, who at the time was working as a maritime consultant, wasn’t all that worried. He and his wife, Lisa, had just returned from backcountry skiing in British Columbia. He felt fine. The pathology report that came a few days later suggested otherwise. Miller had stage IV melanoma. A call to a family friend pointed them to Dana-Farber. After a series of evaluations in late March, Miller’s oncologist, Elizabeth Buchbinder, MD, delivered round two of unfathomable news: The melanoma had spread to his pelvis, lungs, and brain. Today, he is cancer-free. He’s not taking any medication and he goes in for scans twice a year. “There’s no evidence of the cancer. There are no side effects. There’s no anything,” he says. “It worked.” Elizabeth Buchbinder is a clinical oncologist at Dana Farber Cancer Institute spec

The legendary Ray Bourque joins, donates $10,000 to the Jimmy Fund!

ESPN's Sean McDonough joins, doubles down on his Mookie Betts comments

Robert Haddad, Chief, Division of Head and Neck Oncology, Dana-Farber Dr. Haddad received his MD Degree from St. Joseph University French School ofMedicine in Beirut. He completed his residency in internal medicine at St Luke's RooseveltMedical Center in New York City, and completed a fellowship in hematology oncology at theUniversity of Maryland Cancer Center in Baltimore.

Jigar Raythatha (Ray-tha-tha), 46, glioma, Lexington, with Kinnary (wife) and Patrick Wen, MD, Director, Center for Neuro-Oncology, Dana-Farber After two weeks of an unresolved headache, Jigar’s doctor ordered an urgent brain MRI,which revealed some abnormal findings. To get a definitive diagnosis, doctors would need toaccess his brain, so Jigar opted for a biopsy over a craniotomy. The results found he hadIDH-mutant astrocytoma, a biomarker for patients with glioma; these findings would guide theapproach to his brain surgery.· For treatment post-surgery, he takes one pill daily as an IDH inhibitor. Jigar will take thiswhile waiting for a new targeted therapy to be approved and finalized: it’s designed specificallyto target the mutation that is causing his type of cancer. At Dana-Farber, he appreciates howeveryone recognizes that you’re going through something very hard and always meets youwhere you are in your emotional journey.· For work, Jigar is the former CEO of a pharmaceutical company that focused on d

Sean Flaherty from Keches Law joins, talks about "Keches Cares" campaign

Governor Healy joins, talks about trying to bring down the cost of living in Massachusetts

Michael Casey, APRN-BC, FN, Nurse Practitioner, Gastrointestinal Oncology, Dana-Farber Michael Casey, APRN-BC, FNP is a nurse practitioner in Gastrointestinal Oncology atDana-Farber Cancer Institute. He is also the director of the Advanced Practice Nursingdepartment and co-chair of Dana-Farber’s Ethics Committee, as well as a member of theAmerican Association of Nurse Practitioners.· He earned his bachelor’s degree in biological sciences from the University of Rochesterin 1998 and his master’s degree in nursing science from Boston College in 2002. He came toDana-Farber in 2009 and has worked here ever since.· Michael’s favorite part of working at Dana-Farber is the privilege and intimacy ofcontributing to individuals’ and their families’ well-being during what is in many cases thebiggest challenge of their lives. He also appreciates the strong sense of community within theinstitution and is “humbled to share a workplace with so many colleagues who demonstrate thecommitment and impulse to care for other human

Christine Duncan, MD, Medical Director of Clinical Research and Clinical Development, Gene Therapy Program, Boston Children's Hospital Med school in Chicago; Internship and Residency at Boston Children's Hospital; PediatricHematology/Oncology Fellowship at DFCI; just celebrated being at the Farber for 20 years.· Director of Clinical Research and Development, Dana-Farber/Boston Children's Cancerand Blood Disorders Center.· Research and clinical focus on cellular therapies for rare pediatric diseases- especiallyneuro-metabolic disease and brain tumors.· Clinical leader in partnership with local biotech company (bluebird bio) and MGH in theresearch that lead to the first FDA approved therapy for children with cerebraladrenoleukodystrophy (ALD) in the world. Cerebral ALD is a progressive neurologicallydevastating disease that affects boys and ultimately leads to their deaths if not treated early.· Leader in multiple international pediatric stem cell transplant groups.· On the personal side: mom of three young boy

Dana Mohrlein, 35, astrocytoma, Niantic CT, with David Reardon, MD Clinical Director, Center of Neuro-Oncology, Dana-Farber In college, Dana thought she may have vertigo because of all her headaches, but after aseizure at her first security job, she learned she needed emergency brain surgery. After surgeryat her local hospital, she pursued a second opinion at Dana-Farber and has continued herjourney from there since. She had two additional brain surgeries that same summer atBrigham-Women's Hospital. Shortly after, she started high dose radiation locally, in partnershipwith Dana-Farber, and did 11 months of oral chemotherapy.· After treatment, 11 years passed until Dana had a recurrence last spring and underwenta fourth brain surgery. She now takes an inhibitor drug called Tibsovo, a medication specific toher mutation, that requires her to take two pills every day. The drug was released around thetime of Dana’s most recent recurrence, and she expresses it will hopefully be her “miraclemedicine” for the rest of

Martha Young, Program Manager, Pediatric Patient and Family Education, Dana-Farber Martha Young is the Program Manager for Patient and Family Education in the Jimmy FundClinic. As part of this role, she often works with the nursing team to create educationalmaterials for newly diagnosed families. She also oversees the Blum Pediatric Resource Room, aspace that integrates patient education into the everyday family experience in the Jimmy FundClinic. Throughout her 17 years in the clinic, she has worked with the team to create programsand resources aimed to help support patients and their families throughout treatment. Some ofthose programs include Music Therapy, BEADS and BEADS for Sibs, caregiver corner, artprogramming, FACES and FLASHES – groups for teen and “tween” patients to meet outside of